local_hospital
verifiedVerified

Bicetre Hospital

Address
78 Rue Du General Leclerc, 94275 Le Kremlin-Bicetre, France

Rheumatology and Pediatric Inflammatory Disease Research

At Bicetre Hospital, the Service de Rhumatologie is involved in studies focused on immune system diseases and skin and connective tissue diseases, with a strong emphasis on inflammatory conditions in children and adolescents. The research is designed to better understand and improve care for juvenile idiopathic arthritis and related forms of arthritis.

  • Studies in juvenile idiopathic arthritis and related pediatric arthritis conditions
  • Research on enthesitis-related arthritis and juvenile psoriatic arthritis
  • Evaluation of new treatments aimed at improving symptom control and disease outcomes

These trials are helping assess how well emerging therapies work in young patients living with chronic inflammatory joint disease.

Autoimmune and Systemic Disease Studies

Clinical research at this site also covers immune system diseases and broader immune system phenomena, including work on complex autoimmune conditions such as Sjögren’s syndrome. The goal is to improve treatment options for people with moderate to severe systemic disease activity.

  • Research in Sjögren’s syndrome with systemic involvement
  • Studies examining control of broader autoimmune symptoms and organ-related effects
  • Testing whether new therapies can reduce disease activity and improve daily functioning

This area of research reflects a focus on treatments that may better address the full impact of systemic autoimmune disease.

Neurology-Related Amyloidosis Research

The trial portfolio at Bicetre Hospital includes research in nervous system diseases and rare inherited disorders, especially hereditary transthyretin-mediated amyloidosis with polyneuropathy. These studies aim to determine whether new therapies can help preserve nerve function and reduce neurologic impairment.

  • Investigation of hereditary transthyretin-mediated amyloidosis with polyneuropathy
  • Assessment of treatments intended to slow nerve damage and improve neurologic outcomes
  • Rare disease research with a focus on symptom relief and disease control

This work supports efforts to improve care for patients affected by a progressive inherited condition that can strongly affect the nerves.

Translational Pediatric Rheumatology and Treatment Evaluation

Across its clinical studies, the site contributes to research that spans congenital, hereditary, and neonatal diseases and abnormalities as well as inflammatory conditions linked to the immune system. The trials are centered on understanding how therapies behave in younger patients and on evaluating their effectiveness in real clinical settings.

  • Drug behavior and treatment response research in children and adolescents
  • Clinical evaluation of therapies for inflammatory joint disease
  • Studies aimed at improving long-term disease management and patient outcomes

This research profile highlights a mix of pediatric rheumatology, autoimmune disease, and rare disease studies, showing a broad interest in improving care for both common and uncommon conditions.

Site Overview

assignment
65
connected trials
corporate_fare
49
sponsors
science
95
IMPs

Activity Indicator

Last 6 months

9
Trials started
+29% vs previous period.
7
Trials started 6–12 months ago
65
Total trials linked
Highly Active
trending_upGrowing+29%
1
3
5
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 19 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 90 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
38
Sponsors (total)
49
Active sponsors
34

Sponsor Network

Top 34 by active trials.

lock +33 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +9 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
65
Outperforms 90% of sites
public
Therapeutic diversity
20areas
Outperforms 94% of sites
groups
Sponsor diversity
49sponsors
Outperforms 93% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Bicetre Hospital

lock Showing 1 of 65 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-InhibitorsGeron Corp.Phase IIINot RecruitingApr 2021

IMP list

lock Showing 1 of 95 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Filgotinib3Unknown2024-02-142026-04-13

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.